Androgenetic Alopecia Incidence In Transgender And Gender Diverse Populations: A Retrospective Comparative Cohort Study

    February 2023 in “ Journal of The American Academy of Dermatology ”
    Julia L. Gao, Jessika Sanz, Nicholas Tan, Dana S. King, Anna M. Modest, Erica D. Dommasch
    Studysummary This study found that transgender and gender diverse patients on masculinizing hormone therapy had 2.5 times the rate of androgenetic alopecia compared to cisgender women.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigated the incidence of androgenetic alopecia (AGA) among transgender and gender diverse (TGD) patients receiving gender-affirming hormone therapy (GAHT) compared to cisgender patients, using data from 37,826 patients at Fenway Health. Results showed that TGD patients on masculinizing GAHT had 2.5 times the rate of AGA compared to cisgender women, but no significant increase compared to cisgender men. TGD patients on feminizing GAHT did not show a significant difference in AGA rates compared to cisgender men, but had a significantly higher rate compared to cisgender women. The study's limitations include the inability to determine causation and limited generalizability.
    Discuss this study in the Community →